Subxyphoid 2-dimensional echocardiographic identification of left ventricular papillary muscle anomalies in complete common atrioventricular canal

Mitral valve dysfunction is probably the major cause of operative mortality from total repair of complete common atrioventricular (AV) canal in infancy. The presence of a solitary left ventricular (LV) papillary muscle appears to be 1 anatomic factor influencing the success of mitral reconstruction because suturing of the cleft between the superior and inferior components of the anterior mitral leaflet creates a parachute mitral valve deformity, which may result in stenosis or in unduly high tension on the components of the repair. This study reports on (1) the 2-dimensional (2-D) echocardiographic appearance of the LV papillary muscle architecture in patients with complete common AV canal compared with that in normal subjects, and (2) the incidence of solitary LV papillary muscle in patients with complete common AV canal.

Two-dimensional echocardiography was performed in 31 infants with complete common AV canal, 14 normal infants, and 9 infants with a large ventricular septal defect not involving the AV canal region. Of 31 infants with complete common AV canal, 26 (80%) had 2 LV papillary muscles on 2-D echocardiography, 3 (10%) had 3 LV papillary muscles, and 3 (10%) had 1 LV papillary muscle. In patients with 2 LV papillary muscles, the anterolateral papillary muscle was displaced posteriorly compared with that in normal subjects and in patients with ventricular septal defect, whereas the posteromedial papillary muscle was in its normal location.

Among the 25 patients with complete common AV canal with 2 LV papillary muscles, there was 1 operative death. Among the 6 infants with complete common AV canal with LV papillary muscle anomalies, 5 underwent surgical repair with 4 early deaths.

Subxyphoid 2-D echocardiography is a useful technique for evaluating LV papillary muscle architecture in complete common AV canal and permits identification of patients who may be at higher risk for unsuccessful mitral reconstruction.     

Microwave dissociation of antigen-antibody complexes: a new elution technique to permit phenotyping of antibody-coated red cells

To evaluate the effectiveness of microwave irradiation in dissociating IgG from red cells (RBCs), the use of chloroquine diphosphate (CDP) was compared to that of microwaves. Fifteen paired samples of RBCs from 15 patients with positive direct antiglobulin tests (DATs) were treated with both CDP and microwave radiation. Total microwave exposure times ranged from 20 to 100 seconds. Posttreatment DATs were performed, and the reaction grades of the posttreatment DATs were compared. RBC phenotyping was also performed on repeatedly microwaved RBCs to demonstrate possible effects on RBC antigen expression. Microwaves successfully reduced the reaction grade of the DAT in 14 of 15 samples; CDP reduced the reaction grade in 12 of 15 samples. In samples with a DAT of 2+ or greater (n = 13), the microwave method yielded a greater reduction in DAT strength in six cases (results in the other 7 cases were identical with both methods) (p = 0.01). Five of eight cases with a DAT of 3+ showed a greater reduction in the DAT with microwave treatment than with CDP treatment; results in the remaining three cases were identical (p = 0.03). RBC antigenicity remained unchanged after exposure to microwave radiation (A, B, C, c, D, E, e, Fya, Fyb, Jka, Jkb, K, k, S, and s). Microwave treatment required less than 10 minutes per sample, while CDP treatment required 30 to 120 minutes per sample (mean, 88 min). The microwave technique of antigen-antibody dissociation from RBCs provides a rapid and accurate method of facilitating the phenotyping of RBCs coated with warm autoantibodies and is superior to other methods, which destroy RBC antigens.(ABSTRACT TRUNCATED AT 250 WORDS)     

DIAGNOSIS AND MANAGEMENT OF HYPERLIPIDAEMIA

Hyperlipidaemia is acknowledged as the major risk factor for coronary heart disease and atheroma progression. This review considers the strategies that should be followed to reduce overall cardiovascular risk in patients with hyperlipidaemia and deals with the identification and management of treating both polygenic and monogenic lipid disorders in the presence or absence of overt cardiovascular disease.     

Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1

Emerging evidence indicates that the tumour microenvironment (TME) regulates the behaviour of chronic lymphocytic leukaemia (CLL). However, the precise mechanism and molecules involved in this process remain unknown. Gene expression profiles of CLL cells from lymph node (LN), bone marrow (BM) and peripheral blood (PB) indicate overexpression of a tolerogenic signature in CLL cells in lymph nodes (LN-CLL). Based on their role in B cell biology, the progression of CLL, or immune regulation, a few genes of this 83-gene signature were selected for further analyses. We observed a significant correlation between the clinical outcomes and the expression of CAV1 (P = 0·041), FGFR1 isoform 8 (P = 0·032), PTPN6 (P = 0·031) and ZWINT (P < 0·001). CAV1, a molecule involved in the regulation of tumour progression in other cancers, was seven-fold higher in LN-CLL cells compared to BM- and PB-CLL cells. Knockdown of CAV1 expression in CLL cells resulted in significantly decreased migration (P = 0·016) and proliferation (P = 0·04). When CAV1 was knocked down in B and T cell lines, we observed an inability to form immune synapses. Furthermore, CAV1 knockdown in CLL cells impaired their ability to form immune synapses with autologous T lymphocytes and allogeneic, healthy T cells. Subsequent analyses of microarray data showed differential expression of cytoskeletal genes, specifically those involved in actin polymerization. Therefore, we report a novel role for CAV1 in tumour-induced immunosuppression during the progression of CLL.     

Enhanced Bioavailability of Itraconazole in Hydroxypropylβ-Cyclodextrin Solution versus Capsules in Healthy Volunteers

The bioavailabilities and bioequivalences of single 200-mg doses of itraconazole solution and two capsule formulations were evaluated in a crossover study of 30 male volunteers. The two capsule formulations were bioequivalent. The bioavailabilities of the solutions itraconazole and hydroxyitraconazole were 30 to 33% and 35 to 37% greater, respectively, than those of either capsule. However, the maximum concentrations of the drug in plasma (C_max), the times to C_max, and the terminal half-lives were comparable for all three formulations. These data indicate that the bioavailabilities of itraconazole and hydroxyitraconazole are enhanced when administered as an oral solution instead of capsules.